Eli Lilly has secured marketing authorization from India's CDSCO for its Alzheimer's drug, donanemab. This new disease-modifying therapy targets amyloid plaques, offering a significant milestone in addressing the urgent needs of early-stage Alzheimer's patients in India. The drug aims to slow cognitive decline, providing more time and improved quality of life for individuals and their families.